Immunome (IMNM) Total Non-Current Liabilities (2020 - 2023)
Immunome's (IMNM) quarterly Total Non-Current Liabilities came in at $27.3 million in Q4 2023, up 272.64% YoY from $7.3 million in Q4 2022, and down 68.59% on a QoQ basis from $87.0 million in Q3 2023.
Immunome (IMNM) Total Non-Current Liabilities (2020 - 2023) Analysis & Trends
Immunome (IMNM) has 4 years of Total Non-Current Liabilities data on file, last reported at $27.3 million in Q4 2023.
- Quarterly Total Non-Current Liabilities rose 272.64% year-over-year to $27.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $27.3 million (up 272.64% YoY) and the FY2023 annual result came in at $27.3 million, up 272.64% from the prior year.
- Total Non-Current Liabilities fell to $27.3 million in Q4 2023, from $87.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $87.0 million in Q3 2023 to a low of $5.6 million in Q3 2020.
- A 4-year average of $20.3 million and a median of $9.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slipped 24.64% — and 2023, when it jumped 1080.12%.
- Tracing IMNM's Total Non-Current Liabilities over 4 years: stood at $5.6 million in 2020, then soared by 72.85% to $9.7 million in 2021, then declined by 24.64% to $7.3 million in 2022, then jumped by 272.64% to $27.3 million in 2023.
- The last three Total Non-Current Liabilities figures came in at $27.3 million (Q4 2023), $87.0 million (Q3 2023), and $7.3 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 27.32 Mn |
| Sep 30, 2023 | 86.96 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 7.37 Mn |
| Jun 30, 2022 | 8.62 Mn |
| Mar 31, 2022 | 9.71 Mn |
| Dec 31, 2021 | 9.73 Mn |
| Sep 30, 2020 | 5.63 Mn |